Logo image of NKTX

NKARTA INC (NKTX) Stock Overview

NASDAQ:NKTX - US65487U1088 - Common Stock

2.37 USD
+0.05 (+2.16%)
Last: 8/22/2025, 8:27:16 PM
2.37 USD
0 (0%)
After Hours: 8/22/2025, 8:27:16 PM

NKTX Key Statistics, Chart & Performance

Key Statistics
52 Week High6.63
52 Week Low1.31
Market Cap168.18M
Shares70.96M
Float66.31M
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-1.51
PEN/A
Fwd PEN/A
Earnings (Next)11-05 2025-11-05/amc
IPO07-10 2020-07-10
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology


NKTX short term performance overview.The bars show the price performance of NKTX in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 10 20 30

NKTX long term performance overview.The bars show the price performance of NKTX in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 20 -20 -40 -60 -80

The current stock price of NKTX is 2.37 USD. In the past month the price increased by 9.72%. In the past year, price decreased by -55.45%.

NKARTA INC / NKTX Daily stock chart

NKTX Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 19.89 372.00B
AMGN AMGEN INC 13.47 157.94B
GILD GILEAD SCIENCES INC 14.83 142.77B
VRTX VERTEX PHARMACEUTICALS INC 23.32 101.47B
REGN REGENERON PHARMACEUTICALS 12.92 63.65B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 59.25B
ARGX ARGENX SE - ADR 71.2 40.39B
ONC BEONE MEDICINES LTD-ADR 5.78 33.95B
BNTX BIONTECH SE-ADR N/A 26.66B
INSM INSMED INC N/A 25.02B
NTRA NATERA INC N/A 22.61B
BIIB BIOGEN INC 8.7 20.41B

About NKTX

Company Profile

NKTX logo image Nkarta, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of natural killer cell therapies for the treatment of cancer. The company is headquartered in South San Francisco, California and currently employs 157 full-time employees. The company went IPO on 2020-07-10. The firm is developing NKX019, a chimeric antigen receptor-natural killer (CAR NK) product candidate targeting the CD19 antigen for the treatment of patients with autoimmune diseases and NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands. NKX019 is engineered with a humanized CD19-directed CAR for enhanced cell targeting and a proprietary, membrane-bound form of interleukin-15 (IL-15) for greater persistence and activity without exogenous cytokine support. CD19 is a biomarker for normal B cells as well as those implicated in autoimmune disease and B cell-derived malignancies. Its NKX019 autoimmune program is based on the potential to eliminate the pathologic B cells that produce autoantibodies.

Company Info

NKARTA INC

1150 Veterans Boulevard

South San Francisco CALIFORNIA 94080 US

CEO: Paul J. Hastings

Employees: 157

NKTX Company Website

NKTX Investor Relations

Phone: 19254071049

NKARTA INC / NKTX FAQ

What is the stock price of NKARTA INC today?

The current stock price of NKTX is 2.37 USD. The price increased by 2.16% in the last trading session.


What is the ticker symbol for NKARTA INC stock?

The exchange symbol of NKARTA INC is NKTX and it is listed on the Nasdaq exchange.


On which exchange is NKTX stock listed?

NKTX stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for NKARTA INC stock?

13 analysts have analysed NKTX and the average price target is 13.06 USD. This implies a price increase of 450.89% is expected in the next year compared to the current price of 2.37. Check the NKARTA INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is NKARTA INC worth?

NKARTA INC (NKTX) has a market capitalization of 168.18M USD. This makes NKTX a Micro Cap stock.


How many employees does NKARTA INC have?

NKARTA INC (NKTX) currently has 157 employees.


What are the support and resistance levels for NKARTA INC (NKTX) stock?

NKARTA INC (NKTX) has a support level at 2.04 and a resistance level at 2.38. Check the full technical report for a detailed analysis of NKTX support and resistance levels.


Should I buy NKARTA INC (NKTX) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does NKARTA INC (NKTX) stock pay dividends?

NKTX does not pay a dividend.


When does NKARTA INC (NKTX) report earnings?

NKARTA INC (NKTX) will report earnings on 2025-11-05, after the market close.


What is the Price/Earnings (PE) ratio of NKARTA INC (NKTX)?

NKARTA INC (NKTX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.51).


What is the Short Interest ratio of NKARTA INC (NKTX) stock?

The outstanding short interest for NKARTA INC (NKTX) is 12.18% of its float. Check the ownership tab for more information on the NKTX short interest.


NKTX Technical Analysis

ChartMill assigns a technical rating of 6 / 10 to NKTX. When comparing the yearly performance of all stocks, NKTX is a bad performer in the overall market: 84.47% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

NKTX Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to NKTX. While NKTX has a great health rating, there are worries on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

NKTX Financial Highlights

Over the last trailing twelve months NKTX reported a non-GAAP Earnings per Share(EPS) of -1.51. The EPS increased by 33.48% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -23.64%
ROE -29.37%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%25.86%
Sales Q2Q%N/A
EPS 1Y (TTM)33.48%
Revenue 1Y (TTM)N/A

NKTX Forecast & Estimates

13 analysts have analysed NKTX and the average price target is 13.06 USD. This implies a price increase of 450.89% is expected in the next year compared to the current price of 2.37.


Analysts
Analysts83.08
Price Target13.06 (451.05%)
EPS Next Y9.67%
Revenue Next YearN/A

NKTX Ownership

Ownership
Inst Owners90.35%
Ins Owners0.4%
Short Float %12.18%
Short Ratio14.48